Alok Khorana/X
Nov 20, 2026, 11:03
Alok Khorana: First FXI Inhibitor Approved in the US
Alok Khorana, Vice Chair of the Taussig Cancer Institute at Cleveland Clinic, shared a post on LinkedIn:
“Big news that the first FXI inhibitor is finally approved, at least in the US.
Asundexian is approved for use after ischemic stroke, to reduce recurrent events.
Bleeding was no different than placebo (1.9% vs. 1.7%; P = 0.46).
Trials of various FXI inhibitors are currently ongoing in a variety of cancer settings (primary and secondary prevention of thrombosis), with the hope of reducing bleeding but preserving anticoagulant efficacy.”

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 06:51How YERM Shapes the Careers of Future Hematology Researchers – EHA
-
Nov 20, 2026, 06:44Ann Van De Velde: Emerging Advances in Hemoglobinopathies, Sickle Cell Disease and Rare Anemias
-
Nov 20, 2026, 06:29Markus Müller: ABO Blood Groups and the Rare Bombay Phenotype
-
Nov 20, 2026, 05:57Lance Reed: Specialized Blood Components and Clinical Samples for Research and Diagnostics
-
Nov 20, 2026, 05:41Sundas Anjum: Community Engagement and Blood Donation for Thalassemia Care
-
Nov 20, 2026, 05:24A Celebration of Unity and Dedication in Hemophilia Care – Hemophilia Society Mumbai Chapter
-
Nov 20, 2026, 05:09Farhad Sheikh: Prasugrel vs Ticagrelor in Acute Coronary Syndromes
-
Nov 20, 2026, 05:02Jason Acker: Appointed as the Next Editor-in-Chief of Vox Sanguinis
-
Nov 20, 2026, 04:58Sabri Kemahli: International Society of Hematology Celebrates 80 Years of Hematology with Special Webinar